|
The introduction of therapeutically valuable genes into humans using vectors, such as viral vectors, is called gene therapy, a new and rapidly evolving technology with great potential medical value. Once a promising gene vector has been identified and developed, it must be propagated in a host cell line which is capable of producing sufficient quantities of the vector to support both clinical trials and commercial use. Per.C6®, retinoblastoma-like and HEK-293 cell lines are currently popular host cell lines used for this purpose.
Traditionally, viruses useful as vaccines are propagated in cell culture medium that is supplemented with serum. Today, there is increased recognition and concern that adventitious agents contained in animal-derived raw materials may be introduced into the manufacturing process, and ultimately the drug. Therefore, most regulatory agencies now recommend that manufacturers of therapeutic drugs avoid, to the degree possible, the use of animal-derived materials in their manufacturing process.
Sigma has developed animal-derived component free media for the Per.C6®, retinoblastoma-like and HEK-293 cell lines. These media are intended for the growth of cells in suspension cultures. If cell stocks are maintained as attached cells in serum-supplemented media, it is recommended that the adaptation to suspension cultures in serum-free medium be performed as a two step process.
| Product # |
Product Name |
Description |
Application |
|
G 9916 |
Gene Therapy
Medium 3
for Adenovirus Production
Technical Abstract
Performance Data
|
- Liquid;
- Proprietary formulation:
- Without L-glutamine; supplement with 20 ml of 200mM L-glutamine per liter of medium prior to use.
- Sterile filtered;
- Endotoxin tested;
- Cell culture tested
|
Recommended for use with Per.C6® cells, which may be used for the production of therapeutic gene vectors, such as adenovirus vectors.
This product is essentially devoid of proteins and free of all animal-derived components. Hence, its use greatly reduces the risks of contamination of gene therapy products with animal-derived biological agents |
back to top
|
){kind=link}